Stockreport
Global KRAS Inhibitors Market & Clinical Trials Future Market Outlook 2030: 2 Approved KRAS Inhibitors and 90+ Drugs KRAS Inhibitors in Clinical Trials [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
With the ubiquitous prevalence of cancer ailments oscillating year by year, the sophisticated treatment approaches are vastly sought subsequently. With this respect, the market in conjugation with forecast for the domain of global KRAS inhibitor sector emerges as a newfangled mainstay for shareholders as well as researchers in the medical and biotechnological panorama. Currently, the market for this segment is dominated by the US due to the region's strong drug sales, augmenting approval of KRAS inhibitors by the US government and presence of different funding agencies; however, other region, like China, is also an emerging area as evident from preclinical and clinical studies. As the realm of KRAS inhibitor encircles trailblazing advancements along with evolution; a noteworthy industry emphasis in KRAS inhibitor sphere, with opportunities of considerable progress, is expected in the imminent years. The global industry of KRAS inhibitor has acknowledged an incredible growth, fuel
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback [Yahoo! Finance][Yahoo! Finance]
- Amgen Inc. (NASDAQ: AMGN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $405.00 price target on the stock.[MarketBeat]
- AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why [Yahoo! Finance][Yahoo! Finance]
- Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $362.00 price target on the stock.[MarketBeat]
- Amgen Inc. (NASDAQ: AMGN) had its "underperform" rating re-affirmed by analysts at Robert W. Baird. They now have a $215.00 price target on the stock.[MarketBeat]
- More
AMGN
SEC Filings
SEC Filings
- 8/13/24 - Form 4
- 8/13/24 - Form 4
- 8/13/24 - Form 4
- AMGN's page on the SEC website
- More